Califf Worries Too Many Products On The Market With Little Evidence

As FDA parries arguments that its approval standards have changed, allowing for therapies to get on the market faster with little evidence, former FDA chief Robert Califf told a group of stakeholders in the data industry that he, too, is worried that a number of new treatments are getting on the market with no actual understanding of clinical benefit and risk. Califf didn’t bash expedited pathways, though. In fact, he highlighted the benefits of such pathways and noted that his...